ISK received the FDA’s approval to start Phase 1b/2a with AML patients
09/01/2020Related Posts
-
ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
23/10/2022ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
-
Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors
17/02/2022The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.
-
PHASE 1B/2A Clinical trial started
13/04/2021 -
Cooperation with Harvard Medical School (MGH)
27/10/2019ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
